# A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

> **NCT03238651** · PHASE1 · TERMINATED · sponsor: **Calithera Biosciences, Inc** · enrollment: 17 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular, Marginal Zone

## Interventions

- **DRUG:** TAK-659

## Key facts

- **NCT ID:** NCT03238651
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-01
- **Primary completion:** 2020-08-17
- **Final completion:** 2020-08-17
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Termination of the study by the sponsor due to business decision.
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238651, "A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03238651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*